2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

Author’s Disclosures of Potential Conflicts of Interest
Author
Steven A. Curley*
*No relevant relationships to disclose.
Employment or
Leadership
Positions
Consultant or
Advisory Role
1. Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of
surgical indications in the treatment of liver metastases from colorectal
cancer: long-term results. Ann Surg. 2000;231:487-499.
2. Pawlik TM, Abdalla EK, Ellis LM, et al. Debunking dogma: surgery for
four or more colorectal liver metastases is justified. J Gastrointest Surg.
2006;10:240-248.
3. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for
colorectal carcinoma metastases: a multi-institutional study of patterns of
recurrence. Surgery. 1986;100:278-284.
4. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of
colorectal carcinoma metastases to the liver. A prognostic scoring system to
improve case selection, based on 1568 patients. Association Française de
Chirurgie. Cancer. 1996;77:1254-1262.
5. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence
after hepatic resection for metastatic colorectal cancer: analysis of 1001
consecutive cases. Ann Surg. 1999;230:309-318; discussion 318-321.
6. Scheele J, Altendorf-Hofmann A, Grube T, et al. Resection of colorectal
liver metastases. What prognostic factors determine patient selection? [in
German]. Chirurg. 2001;72:547-560.
7. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable
colorectal liver metastases downstaged by chemotherapy: a model to predict
long-term survival. Ann Surg. 2004;240:644-657; discussion 657-658.
8. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes
following hepatic resection, radiofrequency ablation, and combined resection/
ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825.
9. Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy
212
Stock
Ownership Honoraria
REFERENCES
Research
Funding
Expert
Testimony
STEVEN A. CURLEY
Other
Remuneration
in the treatment of multiple colorectal metastases to the liver. Br J Surg.
2003;90:963-969.
10. Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to
neoadjuvant chemotherapy in patients undergoing resection of synchronous
colorectal liver metastases. J Gastrointest Surg. 2003;7:109-115
11. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal
obstruction associated with oxaliplatin-based chemotherapy in patients
with metastatic colorectal cancer. Ann Oncol. 2004;15:460-466.
12. Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis
associated with irinotecan or oxaliplatin pretreatment on resectability of
hepatic colorectal metastases. J Am Coll Surg. 2005;200:845-853.
13. Behrns KE, Tsiotos GG, DeSouza NF, et al. Hepatic steatosis as a
potential risk factor for major hepatic resection. J Gastrointest Surg. 1998;2:
292-298.
14. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a
histological scoring system for nonalcoholic fatty liver disease. Hepatology.
2005;41:1313-1321.
15. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen
predicts steatohepatitis and an increase in 90-day mortality after surgery for
hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-2072.
16. Brouquet A, Overman MJ, Kopetz S. Is resection of colorectal liver
metastases after a second-line chemotherapy regimen justified? Cancer.
2011;117:4484-4492.
17. Brouquet A, Mortenson MM, Vauthey J-N. Surgical strategies for
synchronous colorectal liver metastases in 156 consecutive patients: classic,
combined or reverse strategy? J Am Coll Surg. 2010;201:934-941.